- Home
- NAAS vs PRPO Comparison
NAAS vs PRPO Comparison
Compare NAAS & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | PRPO |
|---|---|---|
| Founded | 2019 | N/A |
| Country | China | United States |
| Employees | N/A | 71 |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 42.0M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NAAS | PRPO |
|---|---|---|
| Price | $3.35 | $23.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 106.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $1.80 | $13.80 |
| 52 Week High | $4.54 | $33.63 |
Technical Indicators
Market Signals| Indicator | NAAS | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 49.43 |
| Support Level | $3.26 | $22.36 |
| Resistance Level | $3.47 | $25.21 |
| Average True Range (ATR) | 0.22 | 1.59 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 50.00 | 66.67 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.